J&J takes full control of retinal disease gene therapy from MeiraGTx

2023-12-21

引进/卖出基因疗法临床3期

Johnson & Johnson’s Janssen Pharmaceuticals unit agreed to buy full rights to MeiraGTx MeiraGTx’s investigational X-linked retinitis pigmentosa (XLRP) gene therapy botaretigene sparoparvovec (bota-vec), paying $130 million in upfront and near-term milestones. The therapy is currently being studied in the Phase III Lumeos trial.

In 2019, Janssen paid $100 million upfront as part of a deal with MeiraGTx to develop gene therapies for inherited retinal diseases, with the agreement including bota-vec, previously known as AAV-RGPR. MeiraGTx CEO Alexandria Forbes said the latest transaction provides “us with significant near-term cash,” extending its cash runway to mid-2026.

MeiraGTx noted that it stands to receive an extra $285 million in payments linked to the first commercial sales of bota-vec in the US and EU. MeiraGTx MeiraGTx also entered into a commercial supply agreement and a technology transfer agreement with Janssen for bota-vec manufacturing.

Forbes suggested that the agreement allows the company to increase focus on its two late-stage clinical programmes: AAV-AQP1 in xerostomia and AAV-GAD in Parkinson’s disease.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构